HUE066738T2 - Egy IL-4R antagonista antitest alkalmazása az atopiás dermatitis kezelésében ennek beadásával - Google Patents

Egy IL-4R antagonista antitest alkalmazása az atopiás dermatitis kezelésében ennek beadásával

Info

Publication number: HUE066738T2
Authority: HU; Hungary
Prior art keywords: administering; atopic dermatitis; antagonist antibody; treating atopic; treating
Prior art date: 2012-09-07

Application number

HUE21167811A

Other languages

English (en)

Inventor

Marius Ardeleanu

Neil Graham

Jennifer D Hamilton

Stephane C Kirkesseli

Sudeep Kundu

Jeffrey Ming

Allen Radin

Ross E Rocklin

Steven P Weinstein

Original Assignee

Regeneron Pharma

Sanofi Biotechnology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-07

Filing date

2013-09-04

Publication date

2024-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE066738(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-04 Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma

2024-09-28 Publication of HUE066738T2 publication Critical patent/HUE066738T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Mycology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)

HUE21167811A 2012-09-07 2013-09-04 Egy IL-4R antagonista antitest alkalmazása az atopiás dermatitis kezelésében ennek beadásával HUE066738T2 (hu)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date
US201261697972P	2012-09-07	2012-09-07
US201261738715P	2012-12-18	2012-12-18
US201361748588P	2013-01-03	2013-01-03
US201361764624P	2013-02-14	2013-02-14
US201361768229P	2013-02-22	2013-02-22
US201361770091P	2013-02-27	2013-02-27
US201361782420P	2013-03-14	2013-03-14
US201361816191P	2013-04-26	2013-04-26
FR1356759		2013-07-10

Publications (1)

Publication Number	Publication Date
HUE066738T2 true HUE066738T2 (hu)	2024-09-28

Family

ID=50233497

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE13765844A HUE039387T2 (hu)	2012-09-07	2013-09-04	Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával
HUE21167811A HUE066738T2 (hu)	2012-09-07	2013-09-04	Egy IL-4R antagonista antitest alkalmazása az atopiás dermatitis kezelésében ennek beadásával

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE13765844A HUE039387T2 (hu)	2012-09-07	2013-09-04	Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával

Country Status (29)

Country	Link
US (3)	US20140072583A1 (hu)
EP (5)	EP2892927B1 (hu)
JP (4)	JP6353838B2 (hu)
KR (3)	KR102385501B1 (hu)
CN (3)	CN118286417A (hu)
AR (1)	AR092475A1 (hu)
AU (4)	AU2013312868B2 (hu)
BR (1)	BR112015005048A8 (hu)
CA (1)	CA2883936C (hu)
CY (1)	CY1121906T1 (hu)
DK (1)	DK2892927T3 (hu)
ES (3)	ES2981062T3 (hu)
HR (1)	HRP20181227T1 (hu)
HU (2)	HUE039387T2 (hu)
IL (1)	IL237328B (hu)
LT (1)	LT2892927T (hu)
MX (1)	MX363193B (hu)
NZ (3)	NZ630178A (hu)
PL (1)	PL2892927T3 (hu)
PT (2)	PT3889181T (hu)
RS (1)	RS57520B1 (hu)
RU (2)	RU2666630C2 (hu)
SG (2)	SG11201501011WA (hu)
SI (1)	SI2892927T1 (hu)
SM (1)	SMT201800396T1 (hu)
TR (1)	TR201808181T4 (hu)
TW (4)	TWI690328B (hu)
UY (1)	UY35013A (hu)
WO (1)	WO2014039461A1 (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7608693B2 (en)	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
EP3354280B1 (en)	2010-10-06	2020-07-29	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
KR102307248B1 (ko)	2012-08-21	2021-10-01	사노피 바이오테크놀로지	Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en)	2012-09-07	2017-06-30	Regeneron Pharma	Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI697334B (zh)	2013-06-04	2020-07-01	美商再生元醫藥公司	藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN105517570B (zh)	2013-06-21	2020-04-07	赛诺菲生物技术公司	通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en)	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4rantagonist
ES2973858T3 (es)	2014-02-28	2024-06-24	Regeneron Pharma	Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
US10584344B2 (en) *	2014-06-17	2020-03-10	Crown Laboratories, Inc.	Genetically modified bacteria and methods for genetic modification of bacteria
TWI745962B (zh)	2014-06-27	2021-11-11	法商賽諾菲公司	測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
AU2015346150B2 (en)	2014-11-14	2021-08-19	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
JP6938383B2 (ja)	2015-04-02	2021-09-22	インターベットインターナショナルベー．フェー．	イヌインターロイキン４受容体アルファに対する抗体
EP4650370A2 (en)	2015-04-14	2025-11-19	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
MA43918A (fr)	2015-04-14	2018-12-05	Chugai Pharmaceutical Co Ltd	Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
MX2018009990A (es)	2016-02-19	2018-12-17	Regeneron Pharma	Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
PH12018501848B1 (en) *	2016-03-01	2024-02-23	Corcept Therapeutics Inc	The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
CN107474134B (zh)	2016-06-08	2021-07-27	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
CA3035202A1 (en) *	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
KR20190053250A (ko)	2016-09-22	2019-05-17	리제너론 파아마슈티컬스, 인크.	Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RS64550B1 (sr)	2016-09-23	2023-09-29	Hoffmann La Roche	Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
TWI784988B (zh)	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
FI3658184T3 (fi) *	2017-07-27	2023-11-30	Alexion Pharma Inc	Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
HUE064655T2 (hu)	2017-10-30	2024-04-28	Sanofi Biotechnology	IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN111741768B (zh)	2017-10-31	2024-12-27	合一生技股份有限公司	治疗IgE介导的过敏性疾病
CN111566095B (zh)	2017-11-03	2024-09-27	阿克拉瑞斯治疗股份有限公司	被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
CN111656382A (zh) *	2018-01-31	2020-09-11	美道寻济株式会社	广告提示方法及广告提示系统
AU2019270940A1 (en) *	2018-05-13	2020-11-26	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN112823005B (zh)	2018-08-10	2024-08-20	阿克拉瑞斯治疗股份有限公司	吡咯并嘧啶itk抑制剂
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
US11497718B2 (en)	2018-11-13	2022-11-15	Dermavant Sciences GmbH	Use of tapinarof for the treatment of atopic dermatitis
CN111494625B (zh) *	2018-12-25	2022-06-21	江苏荃信生物医药股份有限公司	用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
TW202519263A (zh) *	2019-03-21	2025-05-16	美商再生元醫藥公司	含有抗il-33抗體之穩定調配物
CN121102493A (zh)	2019-03-21	2025-12-12	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CN112010977B (zh) *	2019-05-29	2022-04-26	山东博安生物技术股份有限公司	抗白介素4受体(il-4r)的抗体及其应用
BR112022000740A2 (pt)	2019-07-16	2022-07-05	Sanofi Biotechnology	Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
JP2022543815A (ja)	2019-08-05	2022-10-14	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
EP4010373A1 (en)	2019-08-05	2022-06-15	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
US11748800B1 (en) *	2019-09-11	2023-09-05	Life Spectacular, Inc.	Generating skin care recommendations for a user based on skin product attributes and user location and demographic data
US12277100B2 (en)	2019-09-12	2025-04-15	Life Spectacular, Inc.	Maintaining user privacy of personal, medical, and health care related information in recommendation systems
CN111825766B (zh)	2019-10-31	2021-05-11	上海洛启生物医药技术有限公司	抗il-4r单域抗体及其应用
CN115461818A (zh)	2019-12-09	2022-12-09	赛诺菲生物技术公司	治疗数字鉴定的il-4/il-13相关障碍的方法
KR20220158821A (ko)	2020-03-27	2022-12-01	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2021262622A1 (en)	2020-06-23	2021-12-30	Crown Laboratories, Inc.	Probiotic skin formulations
KR20230106644A (ko) *	2020-11-09	2023-07-13	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 상태를 치료하는 방법
CA3205006A1 (en)	2020-12-23	2022-06-30	Numab Therapeutics AG	Antibody variable domains that bind il-4r
EP4019090A1 (en)	2020-12-23	2022-06-29	Numab Therapeutics AG	Antibody variable domains that bind il-4r
EP4019547A1 (en)	2020-12-23	2022-06-29	Numab Therapeutics AG	Multispecific antibodies having specificity for il-4r and il-31
US11581084B2 (en) *	2020-12-29	2023-02-14	Kpn Innovations, Llc.	Systems and methods for generating an alimentary plan for managing skin disorders
KR20230146630A (ko) *	2021-02-18	2023-10-19	어클라리스 쎄라퓨틱스, 인코포레이티드	아토피성 피부염 및 기타 피부 병태를 치료하기 위한 jak 1/3 억제제의 국소 제형 및 이의 사용 방법
JP2024529808A (ja) *	2021-03-01	2024-08-14	アスランファーマシューティカルズピーティーイーリミテッド	抗ＩＬ－１３Ｒα１抗体またはその結合フラグメントを使用するアトピー性皮膚炎の処置
US20230167171A1 (en)	2021-08-23	2023-06-01	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2022425608A1 (en) *	2021-12-30	2024-08-15	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
WO2023191665A1 (en) *	2022-03-31	2023-10-05	Milaboratory, Limited Liability Company	ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
JP2025533648A (ja) *	2022-10-06	2025-10-07	レグラニオン、エルエルシー	化膿性汗腺炎を治療するための方法および組成物
US20240141051A1 (en)	2022-11-01	2024-05-02	Regeneron Pharmaceuticals, Inc.	Methods for treating hand and foot dermatitis by administering an il-4r antagonist
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8808015D0 (en)	1988-04-06	1988-05-05	Ritter M A	Chemical compounds
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
EP0668774A1 (en)	1991-05-03	1995-08-30	Seragen, Inc.	Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) *	1992-03-05	2002-08-19	大日本除蟲菊株式会社	皮膚炎治療剤
US5714146A (en)	1992-08-26	1998-02-03	Board Of Regents Of The University Of Washington	IL-4 bone therapy
EP0604693A1 (en)	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en)	1993-09-07	1995-07-06	Smithkline Beecham Corp	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
JP2003524602A (ja)	1998-09-18	2003-08-19	ダイナバックステクノロジーズコーポレイション	ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
EP3190126A1 (en)	2000-05-26	2017-07-12	Immunex Corporation	Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE372764T1 (de) *	2000-07-26	2007-09-15	Hououdou Co Ltd	Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
KR20030065539A (ko)	2000-12-22	2003-08-06	소시에떼 데 프로듀이 네슬레 소시에떼아노님	내성 유도
US20030103938A1 (en)	2001-05-09	2003-06-05	Alk-Abello A/S	Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (en)	2001-05-11	2002-11-21	Novartis Ag	Compositions for use in treating ige-associated disorders
US20050074462A1 (en)	2001-05-23	2005-04-07	Duotol Ab	Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
EP2298717B1 (en)	2001-11-30	2015-10-28	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
DE60328195D1 (de)	2002-03-29	2009-08-13	Schering Corp	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
AU2003280324A1 (en)	2002-11-26	2004-06-18	Alk-Abello A/S	Pharmaceutical allergen product
CA2514840C (en)	2003-02-01	2017-11-07	Tanox, Inc.	High affinity, anti-human ige antibodies
US7923209B2 (en)	2003-03-14	2011-04-12	Anergis, S.A.	Allergen peptide fragments and use thereof
US20050112694A1 (en)	2003-11-07	2005-05-26	Carter Paul J.	Antibodies that bind interleukin-4 receptor
CA2550933A1 (en)	2003-12-22	2005-07-14	Amgen Inc.	Methods for identifying functional antibodies
CA2554596A1 (en)	2004-02-27	2005-09-15	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 specific polypetides and therapeutic uses thereof
US20090098142A1 (en)	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
JP5234445B2 (ja) *	2004-10-05	2013-07-10	源一郎杣	薬剤
US8030003B2 (en)	2004-12-07	2011-10-04	Children's Hospital Medical Center	Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en)	2005-01-03	2009-01-16	Hoffmann La Roche	Antibodies against IL-13 receptor alpha 1 and uses thereof
BRPI0611069A2 (pt)	2005-05-06	2010-11-09	Zymogenetics Inc	anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
US8679545B2 (en)	2005-11-12	2014-03-25	The Regents Of The University Of California	Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en)	2005-11-12	2012-12-04	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
SI2041177T1 (sl)	2006-06-02	2012-03-30	Regeneron Pharma	Visoko afinitetna protitelesa za humani IL receptor
JP4221018B2 (ja)	2006-08-31	2009-02-12	トヨタ自動車株式会社	頭部保護エアバッグ装置
RS53340B (sr)	2006-10-02	2014-10-31	Regeneron Pharmaceuticals, Inc.	Humana antitela visokog afiniteta za humani il-4 receptor
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
SI2132230T1 (sl)	2007-03-22	2014-07-31	Genentech, Inc.	Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
EP2022507A1 (en)	2007-08-07	2009-02-11	Universität Hamburg	Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en)	2007-11-05	2009-05-14	The Regents Of The University Of Colorado	Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de)	2008-04-11	2008-10-02	Alk-Abelló A/S	Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en)	2008-04-21	2009-10-22	Meritage Pharma, Inc.	Treating eosinophilic esophagitis
US20120004205A1 (en)	2008-12-01	2012-01-05	Cincinnati Children's Hospital Medical Center	Il-13 induced gene signature for eosinophilic esophagitis
WO2010120524A2 (en)	2009-03-31	2010-10-21	Altair Therapeutics, Inc.	Methods of modulating an immune response to a viral infection
US8497528B2 (en)	2010-05-06	2013-07-30	Taiwan Semiconductor Manufacturing Company, Ltd.	Method for fabricating a strained structure
EP2475382B1 (en)	2009-09-07	2015-01-14	DBV Technologies	Method of treating eosinophilic esophagitis
US8993347B2 (en)	2009-12-17	2015-03-31	Cornell University	Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en)	2010-06-24	2021-09-22	ViroPharma Biologics LLC	Methods of treatment for esophageal inflammation
EP3354280B1 (en)	2010-10-06	2020-07-29	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) *	2010-12-23	2012-06-20	Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР")	Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en)	2011-01-06	2014-05-21	Childrens Hosp Medical Center	EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en)	2011-02-22	2013-02-28	Oxagen Limited	CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en)	2011-06-21	2018-03-27	Children's Hospital Medical Center	Diagnostic methods of eosinophilic esophagitis
WO2013051928A1 (en)	2011-10-06	2013-04-11	N.V. Nutricia	Treatment of eosinophilic esophagitis
CN104114169A (zh)	2011-12-16	2014-10-22	阿托佩斯治疗有限公司	用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
TW201334789A (zh)	2012-01-31	2013-09-01	Genentech Inc	抗ｉｇｅ抗體及其使用方法
WO2013155010A1 (en)	2012-04-09	2013-10-17	Children's Hospital Medical Center	Non-invasive biomarkers for eosinophilic esophagitis
KR102307248B1 (ko)	2012-08-21	2021-10-01	사노피 바이오테크놀로지	Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en)	2012-09-07	2017-06-30	Regeneron Pharma	Methods for treating atopic dermatitis by administering an il-4r antagonist
US10132809B2 (en)	2012-10-10	2018-11-20	Rhote Island Hospital	Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
ES2667420T3 (es)	2013-02-05	2018-05-10	Engmab Sàrl	Anticuerpos biespecíficos contra cd3epsilon y bcma
TWI697334B (zh)	2013-06-04	2020-07-01	美商再生元醫藥公司	藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN105517570B (zh)	2013-06-21	2020-04-07	赛诺菲生物技术公司	通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru)	2013-11-14	2015-06-10	Общество С Ограниченной Ответственностью "Фарминтерпрайсез"	Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en)	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4rantagonist
ES2973858T3 (es)	2014-02-28	2024-06-24	Regeneron Pharma	Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
AU2015346150B2 (en)	2014-11-14	2021-08-19	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
MX2018009990A (es)	2016-02-19	2018-12-17	Regeneron Pharma	Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
TWI728172B (zh)	2016-08-18	2021-05-21	美商愛戴爾製藥股份有限公司	治療嗜伊紅性食道炎之方法
CA3035202A1 (en)	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
KR20190053250A (ko)	2016-09-22	2019-05-17	리제너론 파아마슈티컬스, 인크.	Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
IL268349B2 (en)	2017-02-17	2024-08-01	Hutchinson Fred Cancer Res	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
HUE064655T2 (hu)	2017-10-30	2024-04-28	Sanofi Biotechnology	IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
KR102652133B1 (ko)	2018-02-01	2024-03-29	베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드	IL-4Rα 항체 및 그 용도
AU2019270940A1 (en)	2018-05-13	2020-11-26	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN121102493A (zh)	2019-03-21	2025-12-12	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
JP2022543815A (ja)	2019-08-05	2022-10-14	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
EP4010373A1 (en)	2019-08-05	2022-06-15	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
CN115461818A (zh)	2019-12-09	2022-12-09	赛诺菲生物技术公司	治疗数字鉴定的il-4/il-13相关障碍的方法
KR20220158821A (ko)	2020-03-27	2022-12-01	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN115768516A (zh)	2020-05-22	2023-03-07	瑞泽恩制药公司	通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
US20220169739A1 (en)	2020-10-05	2022-06-02	Sanofi Biotechnology	Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
EP4274609A1 (en)	2021-01-08	2023-11-15	Regeneron Pharmaceuticals, Inc.	Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US20230167171A1 (en)	2021-08-23	2023-06-01	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2022425608A1 (en)	2021-12-30	2024-08-15	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20240141051A1 (en)	2022-11-01	2024-05-02	Regeneron Pharmaceuticals, Inc.	Methods for treating hand and foot dermatitis by administering an il-4r antagonist

2013
- 2013-09-04 NZ NZ630178A patent/NZ630178A/en unknown
- 2013-09-04 HU HUE13765844A patent/HUE039387T2/hu unknown
- 2013-09-04 EP EP13765844.9A patent/EP2892927B1/en not_active Revoked
- 2013-09-04 CA CA2883936A patent/CA2883936C/en active Active
- 2013-09-04 DK DK13765844.9T patent/DK2892927T3/en active
- 2013-09-04 WO PCT/US2013/057898 patent/WO2014039461A1/en not_active Ceased
- 2013-09-04 ES ES21167811T patent/ES2981062T3/es active Active
- 2013-09-04 MX MX2015002873A patent/MX363193B/es unknown
- 2013-09-04 RU RU2015108073A patent/RU2666630C2/ru active
- 2013-09-04 HR HRP20181227TT patent/HRP20181227T1/hr unknown
- 2013-09-04 US US14/017,333 patent/US20140072583A1/en not_active Abandoned
- 2013-09-04 PT PT211678115T patent/PT3889181T/pt unknown
- 2013-09-04 CN CN202410387527.8A patent/CN118286417A/zh active Pending
- 2013-09-04 ES ES13765844.9T patent/ES2675779T3/es active Active
- 2013-09-04 SM SM20180396T patent/SMT201800396T1/it unknown
- 2013-09-04 TR TR2018/08181T patent/TR201808181T4/tr unknown
- 2013-09-04 EP EP18161065.0A patent/EP3354663A1/en not_active Withdrawn
- 2013-09-04 LT LTEP13765844.9T patent/LT2892927T/lt unknown
- 2013-09-04 EP EP24163612.5A patent/EP4374919B1/en active Active
- 2013-09-04 AU AU2013312868A patent/AU2013312868B2/en active Active
- 2013-09-04 KR KR1020217023487A patent/KR102385501B1/ko active Active
- 2013-09-04 KR KR1020157008872A patent/KR102122708B1/ko active Active
- 2013-09-04 HU HUE21167811A patent/HUE066738T2/hu unknown
- 2013-09-04 PT PT241636125T patent/PT4374919T/pt unknown
- 2013-09-04 BR BR112015005048A patent/BR112015005048A8/pt not_active Application Discontinuation
- 2013-09-04 SI SI201331084T patent/SI2892927T1/sl unknown
- 2013-09-04 CN CN202410387417.1A patent/CN118286430A/zh active Pending
- 2013-09-04 RU RU2018131237A patent/RU2698907C2/ru active
- 2013-09-04 EP EP21167811.5A patent/EP3889181B1/en not_active Revoked
- 2013-09-04 ES ES24163612T patent/ES3053480T3/es active Active
- 2013-09-04 NZ NZ748451A patent/NZ748451A/en unknown
- 2013-09-04 CN CN201380046623.6A patent/CN104995212A/zh active Pending
- 2013-09-04 SG SG11201501011WA patent/SG11201501011WA/en unknown
- 2013-09-04 JP JP2015531149A patent/JP6353838B2/ja active Active
- 2013-09-04 KR KR1020227011429A patent/KR102576903B1/ko active Active
- 2013-09-04 SG SG10201701798TA patent/SG10201701798TA/en unknown
- 2013-09-04 NZ NZ731864A patent/NZ731864A/en unknown
- 2013-09-04 PL PL13765844T patent/PL2892927T3/pl unknown
- 2013-09-04 EP EP25192817.2A patent/EP4649999A3/en active Pending
- 2013-09-04 RS RS20180802A patent/RS57520B1/sr unknown
- 2013-09-05 TW TW102131927A patent/TWI690328B/zh active
- 2013-09-05 TW TW112129255A patent/TWI852712B/zh active
- 2013-09-05 TW TW107106951A patent/TWI699212B/zh active
- 2013-09-05 TW TW111134046A patent/TWI814575B/zh active
- 2013-09-06 AR ARP130103184A patent/AR092475A1/es unknown
- 2013-09-06 UY UY0001035013A patent/UY35013A/es unknown
2015
- 2015-02-19 IL IL237328A patent/IL237328B/en unknown
2017
- 2017-05-31 US US15/610,267 patent/US20170333557A1/en not_active Abandoned
2018
- 2018-06-08 JP JP2018109925A patent/JP6637113B2/ja active Active
- 2018-06-18 AU AU2018204346A patent/AU2018204346B2/en active Active
- 2018-07-27 CY CY20181100782T patent/CY1121906T1/el unknown
2019
- 2019-12-10 AU AU2019279946A patent/AU2019279946B2/en active Active
2021
- 2021-09-23 AU AU2021236538A patent/AU2021236538B2/en active Active
2022
- 2022-09-23 US US17/951,987 patent/US12502429B2/en active Active
2023
- 2023-03-29 JP JP2023052545A patent/JP2023082091A/ja active Pending
2024
- 2024-11-13 JP JP2024197857A patent/JP2025024077A/ja active Pending

Also Published As

Publication number	Publication date
EP3889181A1 (en)	2021-10-06
DK2892927T3 (en)	2018-07-16
RU2018131237A (ru)	2018-10-04
AU2021236538A1 (en)	2021-10-21
TR201808181T4 (tr)	2018-07-23
RU2698907C2 (ru)	2019-09-02
TWI852712B (zh)	2024-08-11
SMT201800396T1 (it)	2018-09-13
JP2025024077A (ja)	2025-02-19
EP2892927A1 (en)	2015-07-15
AU2013312868A1 (en)	2015-03-12
AU2018204346A1 (en)	2018-07-05
KR20220049047A (ko)	2022-04-20
PT3889181T (pt)	2024-05-29
LT2892927T (lt)	2018-09-10
KR102576903B1 (ko)	2023-09-13
AU2018204346B2 (en)	2019-10-03
US20170333557A1 (en)	2017-11-23
TW201414493A (zh)	2014-04-16
BR112015005048A2 (pt)	2017-11-21
IL237328A0 (en)	2015-04-30
UY35013A (es)	2014-03-31
RS57520B1 (sr)	2018-10-31
AU2013312868B2 (en)	2018-03-22
JP6353838B2 (ja)	2018-07-04
KR20150048887A (ko)	2015-05-07
JP2015534548A (ja)	2015-12-03
AU2021236538B2 (en)	2023-11-09
SI2892927T1 (sl)	2018-10-30
TWI690328B (zh)	2020-04-11
TWI814575B (zh)	2023-09-01
AR092475A1 (es)	2015-04-22
TW202325341A (zh)	2023-07-01
KR102385501B1 (ko)	2022-04-14
PL2892927T3 (pl)	2018-11-30
IL237328B (en)	2020-06-30
CY1121906T1 (el)	2020-07-31
EP4374919A2 (en)	2024-05-29
RU2666630C2 (ru)	2018-09-11
TW202412839A (zh)	2024-04-01
JP2023082091A (ja)	2023-06-13
TW201822816A (zh)	2018-07-01
SG10201701798TA (en)	2017-04-27
NZ731864A (en)	2022-07-01
NZ748451A (en)	2023-04-28
KR102122708B1 (ko)	2020-06-17
EP2892927B1 (en)	2018-05-09
ES2981062T3 (es)	2024-10-07
RU2015108073A (ru)	2016-10-27
US20230058395A1 (en)	2023-02-23
JP6637113B2 (ja)	2020-01-29
TWI699212B (zh)	2020-07-21
CN104995212A (zh)	2015-10-21
MX363193B (es)	2019-03-14
EP3889181B1 (en)	2024-04-24
EP4374919B1 (en)	2025-10-29
HK1209132A1 (en)	2016-03-24
HRP20181227T1 (hr)	2018-10-05
EP4374919A3 (en)	2024-08-21
CA2883936C (en)	2022-01-11
EP4649999A2 (en)	2025-11-19
RU2018131237A3 (hu)	2019-03-14
HUE039387T2 (hu)	2018-12-28
NZ630178A (en)	2017-06-30
EP4649999A3 (en)	2026-02-18
CN118286417A (zh)	2024-07-05
KR20210095731A (ko)	2021-08-02
ES3053480T3 (en)	2026-01-22
MX2015002873A (es)	2015-11-13
BR112015005048A8 (pt)	2018-01-30
AU2019279946A1 (en)	2020-01-16
ES2675779T3 (es)	2018-07-12
US12502429B2 (en)	2025-12-23
PT4374919T (pt)	2025-11-19
CA2883936A1 (en)	2014-03-13
US20140072583A1 (en)	2014-03-13
CN118286430A (zh)	2024-07-05
WO2014039461A1 (en)	2014-03-13
EP3354663A1 (en)	2018-08-01
AU2019279946B2 (en)	2021-07-01
JP2018154648A (ja)	2018-10-04
SG11201501011WA (en)	2015-03-30

Publication	Publication Date	Title
HUE066738T2 (hu)	2024-09-28	Egy IL-4R antagonista antitest alkalmazása az atopiás dermatitis kezelésében ennek beadásával
IL290653A (en)	2022-04-01	A biomarker for use in the treatment of anemia
IL237258A0 (en)	2015-04-30	Methods for treating or preventing asthma by administering an antagonist to -il-r4
EP2886389A4 (en)	2016-03-16	SLIDING SEAT DEVICE
ZA201906339B (en)	2021-07-28	Methods for treating pruritus
PL2866854T3 (pl)	2021-01-11	Polimery do zastosowania w sposobach
IL236714A0 (en)	2015-02-26	Anti-her2 antibodies with reduced fucosylation for use in cancer therapy
EP2697239A4 (en)	2014-09-03	N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
IL278968B (en)	2021-09-30	Methods for the treatment of atopic dermatitis through the administration of an IL-4R antagonist
HUE046410T2 (hu)	2020-03-30	Eljárások orrpolipózis kezelésére IL-4R-antagonista beadásával
HUE046993T2 (hu)	2020-04-28	Készítmény radioterápia és kemoterápia által okozott leukopenia megelõzésében és kezelésében történõ alkalmazásra
ZA201405414B (en)	2015-10-28	Method and device for reducing iron-oxide-containing feedstocks
IL271284A (en)	2020-01-30	Methods for treating or preventing asthma by administering an antagonist to -il-r4
EP2736517A4 (en)	2014-12-24	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS
EP2813244A4 (en)	2015-09-02	PHARMACEUTICAL FORM WITHOUT SIDE EFFECTS AND PREPARATION METHOD THEREOF
EP2822457A4 (en)	2015-11-11	MEANS AND METHODS FOR ASSESSING HYPERTHYROIDISM
GB201201826D0 (en)	2012-03-21	Methods and compositions for treating disorders associated with impaired insulin sensitivity